# Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/CABA/cabaletta-bio-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: CABA
Company: Cabaletta Bio
Source: Cabaletta Bio
Published: 2026-05-14 11:05 EST
Original Source URL: https://www.cabalettabio.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-03 11:00 EST — [Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress](https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-new-rese-cel-data-and-development-updates-across-autoimmune-portfolio-including-encouraging-early-pc-free-lupus-findings-at-eular-2026-congress) — Source: Cabaletta Bio
- 2026-05-14 11:05 EST — [Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CABA/cabaletta-bio-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Cabaletta Bio
- 2026-05-14 11:00 EST — [Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting](https://biopharmsignal.com/news/CABA/cabaletta-bio-presents-preconditioning-free-clinical-data-and-automated-manufacturing-translational-data-for-rese-cel-at-asgct-2026-annual-meeting) — Source: Cabaletta Bio
- 2026-05-04 10:35 EST — [Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering](https://biopharmsignal.com/news/CABA/cabaletta-bio-announces-pricing-of-150-million-underwritten-offering) — Source: Cabaletta Bio
- 2026-04-28 12:00 EST — [Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel](https://biopharmsignal.com/news/CABA/cabaletta-bio-and-cellares-announce-10-year-commercial-supply-agreement-for-rese-cel) — Source: Cabaletta Bio
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)